Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on February 3 and set a price target of ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly plans to launch Mounjaro, an anti-diabetes and weight loss drug, in India by 2025. The medication, which is ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

“We anticipate a positive response from the Indian market,” Eli Lilly (India) told FE, as the company gets ready to bring its anti-obesity drug tirzepatide, or Mounjaro, to India this yea ...

Eli Lilly said it received Food and Drug Administration ... The treatment, developed by the pharmaceutical company under the brand name Omvoh, is now approved to treat two types of inflammatory ...

Eli Lilly forecasts $45 billion in 2024 revenue ... Get the Real Story Behind Every Major Earnings Report The company's expected 2024 revenue is $400 million, or about 3%, below the guidance ...

(Photo source: Reuters) Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other ... build times helped the company deliver more homes ...

Eli Lilly and Company (NYSE:LLY) shares slid 6.6% to $744.91, after it said it expects Q4 revenue at $13.5 billion- weaker than street expectations of $14.08 billion. The miss was driven largely ...